<DOC>
	<DOC>NCT00411099</DOC>
	<brief_summary>This study will assess efficacy, safety and tolerability of agomelatine (AGO178) 25 mg and 50 mg in patients with Major Depressive Disorder (MDD). This study includes an 8-week double-blind phase and a 52-week open-label phase.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>S 20098</mesh_term>
	<criteria>Diagnosis of Major Depressive Disorder, single or recurrent episode, according to DSMIV criteria HAMD17 total score &gt; or = 22 at Screening and Baseline CGISeverity score &gt; or = 4 at Screening and Baseline Only patients who complete the core protocol are eligible to participate in the OpenLabel Extension Phase History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating disorder, or obsessive compulsive disorder Any current Axis I disorder other than major depressive disorder which is the focus of treatment Substance or alcohol abuse in the last 30 days, dependence in the last 6 months Concomitant psychotropic medication, including herbal preparations and melatonin Psychotherapy of any type Female patients of childbearing potential who are not using effective contraception Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>agomelatine, major depressive disorder, MDD, depression</keyword>
</DOC>